These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35837312)

  • 1. Treating Thyroid Associated Ophthalmopathy in Pediatric Patients.
    Dong T; Fu Z; Wang X
    Front Endocrinol (Lausanne); 2022; 13():900204. PubMed ID: 35837312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
    Janssen JAMJL; Smith TJ
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
    Smith TJ
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-Like Growth Factor Pathway and the Thyroid.
    Smith TJ
    Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for Thyroid-Associated Ophthalmopathy.
    Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
    N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
    Smith TJ
    Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.
    Fernando R; Smith TJ
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4037-e4047. PubMed ID: 35809263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2021 update on thyroid-associated ophthalmopathy.
    Neag EJ; Smith TJ
    J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
    Ding Y; Yang S; Gao H
    Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
    Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF1 receptor and thyroid-associated ophthalmopathy.
    Mohyi M; Smith TJ
    J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Novel Medical Treatments for Thyroid Eye Disease.
    Park JW; Yoon JS
    Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.